Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06527157 · ClinicalTrials.gov registry record

Investigations of Reproductive Cancers in Women

A clinical trial of Uterine Cancer, sponsored by PinkDx.

Recruiting
Registry status
4,500
Enrollment target
16
Study locations

NCT06527157: Recruiting study of Uterine Cancer, sponsored by PinkDx.

NCT06527157 is a study of Uterine Cancer that is actively recruiting participants, run by PinkDx. The registered enrollment target is 4,500 participants, above the 105-participant average among 27 other Uterine Cancer trials with a reported enrollment target (4186% higher). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06527157, a study of Uterine Cancer, is actively recruiting participants, sponsored by PinkDx.

RECRUITING
Registry status
4,500 participants
Enrollment target
16
Study locations

Study Summary

The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.

Primary Outcome

ability to detect cancer

Conditions Studied

Uterine Cancer

Study Locations (16)

Texas

  • Baylor College of Medicine/Texas Children's Hospital - Houston
  • Houston Methodist - Houston
  • University of Texas Health Science Center at San Antonio - San Antonio

Ohio

  • Summa Health - Akron
  • The Ohio State University - Columbus

Tennessee

  • University of Tennessee Health Science Center - Memphis
  • Meharry Medical College - Nashville

Alabama

  • University of Alabama, Birmingham - Birmingham

California

  • Sutter Health - Redwood City

Florida

  • Advent Health Orlando - Orlando

Illinois

  • Ob-Gyne Associates of Lake Forest, Ltd - Lake Forest

Indiana

  • Indiana University, Eskenazi Health - Indianapolis

Trial Details

FieldValue
Enrollment Target 4,500 participants
Start Date 2024-07-30
Est. Completion 2026-11-15
PinkDx

2 total trials

What NCT06527157 shows while recruiting

NCT06527157 is an observational study that tracks outcomes without assigning an intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus, above the 105-participant average among 27 other Uterine Cancer trials with a reported enrollment target (4186% higher).

The record links to 1 condition, with Uterine Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06527157 lists 16 locations in 12 states (Texas, Ohio, Tennessee).

Frequently Asked Questions

What is clinical trial NCT06527157 about?

NCT06527157 is a clinical study titled "Investigations of Reproductive Cancers in Women". The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.

What is the current status of trial NCT06527157?

This trial is currently recruiting. The enrollment target is 4,500 participants. The study started on 2024-07-30. Estimated completion is 2026-11-15.

What conditions does trial NCT06527157 study?

This clinical trial studies the following conditions: Uterine Cancer.

Who is sponsoring clinical trial NCT06527157?

This trial is sponsored by PinkDx, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06527157 being conducted?

This trial has 16 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06527157's enrollment target sits among peer trials

4,500 1st of 27 higher than 27 of 27 other Uterine Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06533111 · 4,500 participants · NA

    Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool

  • NCT06588452 · 4,500 participants

    Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models

  • NCT07165028 · 4,500 participants · Phase 3

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  • NCT07207564 · 4,500 participants

    Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06527157

Source: ClinicalTrials.gov NCT06527157, the US trial registry maintained by the National Library of Medicine. NCT06527157 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.